IAG’s Oncology and AI Expert Team join ESMO ’23

IAG's Oncology and AI Expert Team join ESMO '23

Meet IAG’s Oncology Expert Team at ESMO, Madrid 2023

Dr. Olga Kubassova, Dr. Kateryna Musaieva and Julia O’Lynn to Represent IAG at ESMO 2023

Image Analysis Group (IAG) is proud to announce the participation of its CEO Dr. Olga Kubassova and their oncology imaging and nuclear medicine experts, Dr. Kateryna Musaieva, VP of Radiology, and Julia O’Lynn, Director of Bio Partnering at the upcoming European Society for Medical Oncology (ESMO) meeting scheduled to take place in Madrid from October 20th to 24th, 2023.

During the ESMO event, IAG’s dedicated team will engage in crucial discussions with leading biotechnology companies. Their primary focus will be addressing the complex challenges that biotech companies encounter in oncology and neuro-oncology trials.

Drs. Kubassova, Musaieva and O’Lynn will present IAG’s innovative strategies for incorporating advanced imaging biomarkers to expedite drug development and approval processes.

IAG is renowned for its collaboration with biotechnology and pharmaceutical companies, deploying cutting-edge technologies such as Artificial Intelligence (AI) and Precision Medicine to accelerate the approval of life-changing therapies. At the core of IAG’s approach are:

  1. DYNAMIKA: An efficient, purpose-built cloud-based system equipped with embedded quality controls for trial data management.
  2. Patented Methodologies: Providing quantitative assessments of treatment efficacy and safety.
  3. Worl-class Expertise: Detecting treatment effects, including pseudo-progression and pseudo-response.
  4. Regulatory Compliance: Ensuring targeted drug development and the scientific credibility of trial data.

IAG’s commitment is to empower its bio-pharmaceutical partners to make informed decisions regarding treatment efficacy by leveraging advanced imaging techniques in their clinical trials.

“We are excited to participate in ESMO 2023 and engage with industry leaders to address the evolving needs of biotechnology companies in the realm of oncology and neuro-oncology trials,” said Julia O’Lynn, Sn Director of Bio-Partnering and Strategy.

IAG’s expertise and innovative solutions are poised to make a significant impact on the development of life-saving therapies,” stated Dr. Kateryna Musaieva.

For those who seek IAG’s advanced analysis strategies to overcome challenges in oncology trials, please contact IAG at imaging.experts@ia-grp.com.

About ESMO:

ESMO, the European Society for Medical Oncology, is a preeminent professional organization dedicated to medical oncology. With over 30,000 members representing oncology professionals from more than 168 countries, ESMO is a global leader in oncology education and information. Founded in 1975, ESMO brings together experts and stakeholders in oncology, promoting a multi-professional approach to cancer care on a global scale.

For more information about the ESMO conference, please visit ESMO’s official website.

About Image Analysis Group (IAG):

Image Analysis Group (IAG) is a unique partner to life sciences companies, leveraging expertise in medical imaging and the power of Dynamika™, its proprietary cloud-based platform, to mitigate risks in clinical development and expedite the delivery of life-saving therapies to patients. IAG provides early drug efficacy assessments, intelligent patient recruitment, and predictive analysis of advanced treatment manifestations, thus reducing investment risk and accelerating study outcomes. Through its bio-partnering approach, IAG offers a comprehensive view of asset development, encompassing R&D solutions, operational breadth, radiological expertise, and risk-sharing financing and partnering models.

For more information about IAG, please visit wp1.ia-grp.com.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin